Literature DB >> 15916693

An elevated venous haemoglobin concentration cannot be used as a surrogate marker for absolute erythrocytosis: a study of patients with polycythaemia vera and apparent polycythaemia.

Peter L Johansson1, Soodabeh Safai-Kutti, Jack Kutti.   

Abstract

The diagnosis of polycythaemia vera (PV) has been established upon sets of clinical criteria, which require the presence of absolute erythrocytosis (AE). The most recent clinical criteria for PV, published by the World Health Organization (WHO) in 2001, also required AE, and stated that the measured red cell mass (RCM) could be replaced by a surrogate marker for AE; a haemoglobin (Hb) value of >18.5 g/dl in males and >16.5 g/dl in females. The present study evaluated the potential of venous haematocrit (Hct) and Hb values as possible surrogate markers for AE in a series of 77 consecutive patients with PV and 66 patients with apparent polycythaemia (AP), in all of whom the RCM had been previously determined. In only 35% of the male PV patients would Hb values >18.5 g/dl indicate the presence of AE. Conversely, 14% of male AP patients would be misdiagnosed as having AE. A Hb > 16.5 g/dl would predict the presence of AE in 63% of the female PV patients, but 35% of female AP cases would be misdiagnosed as having AE. However, when the Hct was > or =0.60 an AE was always present, and this was true for both male and female subjects.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15916693     DOI: 10.1111/j.1365-2141.2005.05517.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  23 in total

1.  Red cell mass measurement in patients with clinically suspected diagnosis of polycythemia vera or essential thrombocythemia.

Authors:  Alberto Alvarez-Larrán; Agueda Ancochea; Anna Angona; Carme Pedro; Francesc García-Pallarols; Luz Martínez-Avilés; Beatriz Bellosillo; Carlos Besses
Journal:  Haematologica       Date:  2012-06-11       Impact factor: 9.941

2.  Diagnosis and Management of Polycythemia Vera: Proceedings from a Multidisciplinary Roundtable.

Authors:  Lisa A Raedler
Journal:  Am Health Drug Benefits       Date:  2014-10

Review 3.  WHO classification of myeloproliferative neoplasms (MPN): A critical update.

Authors:  Hans Michael Kvasnicka
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

4.  JAK2V617F mutation status and allele burden in classical Ph-negative myeloproliferative neoplasms in Japan.

Authors:  Yoko Edahiro; Soji Morishita; Kochi Takahashi; Yumi Hironaka; Yuriko Yahata; Yoshitaka Sunami; Shuichi Shirane; Miyuki Tsutsui; Masaaki Noguchi; Michiaki Koike; Kiyotoshi Imai; Keita Kirito; Naohiro Noda; Yuji Sekiguchi; Satoshi Tsuneda; Akimichi Ohsaka; Marito Araki; Norio Komatsu
Journal:  Int J Hematol       Date:  2014-03-28       Impact factor: 2.490

Review 5.  Investigation and Management of Erythrocytosis.

Authors:  Mary Frances McMullin
Journal:  Curr Hematol Malig Rep       Date:  2016-10       Impact factor: 3.952

Review 6.  Rethinking the diagnostic criteria of polycythemia vera.

Authors:  T Barbui; J Thiele; A M Vannucchi; A Tefferi
Journal:  Leukemia       Date:  2013-12-19       Impact factor: 11.528

Review 7.  Polycythemia Vera.

Authors:  Jerry L Spivak
Journal:  Curr Treat Options Oncol       Date:  2018-03-07

8.  JAK2 V617F and the evolving paradigm of polycythemia vera.

Authors:  Robert T Means
Journal:  Korean J Hematol       Date:  2010-06-30

9.  Time for revival of the red blood cell count and red cell mass in the differential diagnosis between essential thrombocythemia and polycythemia vera?

Authors:  Hans Carl Hasselbalch
Journal:  Haematologica       Date:  2019-11       Impact factor: 9.941

10.  Comparison of blood volume characteristics in anemic patients with low versus preserved left ventricular ejection fractions.

Authors:  Dmitry Abramov; Rose S Cohen; Stuart D Katz; Donna Mancini; Mathew S Maurer
Journal:  Am J Cardiol       Date:  2008-07-31       Impact factor: 2.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.